Filing Flows › Nuvation Bio (NUVB) › R&D spending
Nuvation Bio (NUVB) R&D spending by quarter
Nuvation Bio's R&D spending was $32.7M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $24.6M (Q1 2025) to $35.0M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.7M | +7% | +13% |
| Q2 2026 | $30.7M | -13% | +12% |
| Q1 2026 | $35.0M | +2% | +42% |
| Q4 2025 | $34.3M | +19% | — |
| Q3 2025 | $28.8M | +5% | — |
| Q2 2025 | $27.4M | +11% | — |
| Q1 2025 | $24.6M | — | — |
Q3 2026 at a glance
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Nuvation Bio's R&D spending?
Nuvation Bio's R&D spending was $32.7M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Nuvation Bio's R&D spending changed?
Over the last 7 quarters it ranged from $24.6M (Q1 2025) to $35.0M (Q1 2026).